Phathom Pharmaceuticals, Inc. (PHAT) analyst actions
Rating and price-target actions on PHAT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PHAT overview →
3 measured PHAT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD | Press release | +0.58% | +0.27% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out | Press release | +0.00% | -1.73% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Reach Out | Press release | +0.29% | +2.63% |
Keep exploring
More PHAT: earnings → · SEC filings → · PHAT overview →